Biofrontera Inc. Warrants
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with t… Read more
Biofrontera Inc. Warrants (BFRIW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 1.481x
Based on the latest financial reports, Biofrontera Inc. Warrants (BFRIW) has a cash flow conversion efficiency ratio of 1.481x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.82 Million) by net assets ($-2.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biofrontera Inc. Warrants - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Biofrontera Inc. Warrants's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biofrontera Inc. Warrants Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofrontera Inc. Warrants ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capital Trust Limited
NSE:CAPTRUST
|
0.201x |
|
Cheche Group Inc. Warrant
NASDAQ:CCGWW
|
-0.013x |
|
York Timber Holdings Ltd
JSE:YRK
|
0.025x |
|
ANDERSONS (AKG.SG)
STU:AKG
|
-0.001x |
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
0.549x |
|
Joshua Gold Resources Inc
PINK:JSHG
|
-0.004x |
|
Sylla Gold Corp.
PINK:SYGCF
|
0.000x |
|
Cartica Acquisition Corp Warrant
NASDAQ:CITEW
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Biofrontera Inc. Warrants (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biofrontera Inc. Warrants from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.43 Million | $-10.27 Million | -2.317x | +55.40% |
| 2023-12-31 | $4.79 Million | $-24.89 Million | -5.194x | -665.62% |
| 2022-12-31 | $23.88 Million | $-16.20 Million | -0.678x | +71.21% |
| 2021-12-31 | $11.34 Million | $-26.71 Million | -2.356x | -11.02% |
| 2020-12-31 | $5.83 Million | $-12.37 Million | -2.122x | -270.00% |
| 2019-12-31 | $-30.18 Million | $-37.68 Million | 1.248x | -- |